TSVT News and Press, 2seventy bio Inc. From 12/27/21

The healthcare sector has gained significant importance since the onset of the pandemic. Moreover, the industry is evolving with unique product launches and technological advancements. The healthcare sector has seen several IPOs this year. Healthcare companies 2seventy (TSVT), Regencell (RGC)...

New analyses from pivotal KarMMa study continue to show clinically meaningful health-related quality of life benefits and positive treatment experience with ABECMA, building upon growing body of evidence supporting the first and only approved CAR T cell therapy for multiple myeloma ...

2seventy bio (NASDAQ:TSVT): Q3 Net Loss of $60M Revenue of $19.3M (+4.9% Y/Y) beats by $10.76M. Press Release For further details see: 2seventy bio beats on revenue

– SC-DARIC33 IND accepted by FDA; Phase 1 study now enrolling 2seventy bio, Inc . (Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30, 2021. “We launched 2s...